Bionano Announces Closing of $10 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules

Core Viewpoint - Bionano Genomics, Inc. has successfully closed a registered direct offering, raising approximately $10 million, with potential additional proceeds from warrants also amounting to around $10 million if fully exercised [1][3]. Group 1: Offering Details - The offering consisted of 39,682,540 shares of common stock and warrants to purchase an equal number of shares, priced at $0.252 per share [1]. - The warrants have an exercise price of $0.252 per share and will be exercisable upon stockholder approval, expiring five years after such approval [1]. - H.C. Wainwright & Co. served as the exclusive placement agent for this offering [2]. Group 2: Use of Proceeds - The net proceeds from the offering will be utilized for general corporate purposes, including working capital, research and development, repayment of existing debt, and capital expenditures [3]. Group 3: Regulatory Information - The securities were offered under a shelf registration statement filed with the SEC, which became effective on May 8, 2023 [4]. - A final prospectus supplement related to the offering has been filed with the SEC and is available on their website [4]. Group 4: Company Overview - Bionano Genomics provides genome analysis solutions aimed at enhancing research and clinical applications, focusing on optical genome mapping and diagnostic services [6]. - The company also offers a platform-agnostic genome analysis software solution and nucleic acid extraction services using proprietary technology [6].